Closing price, page-26

Jayste, who knows how many millions we may have shortly in the bank with upfront payments, exclusivity fees, R and D costs etc. Cash IS coming!

The IP has now been more than validated by a major global resulting in a product launch, this should also see some added share value as well as the income from future sales. Every time one of our technologies (EM, FIM, DERM) is incorporated into a product the value of that technology/IP increases.
As was mentioned earlier, OBJ can now look at some longer term opportunities free of financial insecurities or dependence on consulting partners. Bring on pharmaceuticals! Try and put a limit on its applications...I cant.